Beta propeller protein-associated neurodegeneration (BPAN)

Transforming the trajectory of neurodegeneration, starting with BPAN

BPAN (beta-propeller protein-associated neurodegeneration) is a life-threatening pediatric disease that can have a devastating impact on children, including diagnoses such as epilepsy, developmental delay, and autism. In some cases, the disease ultimately strips away hard-won skills, leading to movement abnormalities resembling Parkinson's disease, dementia similar to that seen in Alzheimer's disease, and—heartbreakingly—a life cut short.

BPAN is currently untreatable, and there is no way to predict who will develop severe decline. Yet there is reason for hope. A critical window, often lasting years, exists between early symptoms and later severe decline—giving us the chance to intervene before irreversible damage is done. The key to cures lies in understanding the underlying biology.

Led by pediatric neurologist Dr. Juliet Knowles, our team will launch a first-of-its-kind effort to uncover BPAN disease signatures and discover new therapeutic candidates using animal and patient-derived models. This bold, collaborative mission unites many of Stanford’s top minds across disciplines and leverages the most advanced technologies available to change the future for children with BPAN. Furthermore, this work opens new doors to improve brain health across the life span. The insights uncovered by our work on BPAN will have broad impact: the same biological mechanisms at the root of BPAN (related to autophagy and cellular metabolism) are thought to contribute substantially to common neurodegenerative diseases encountered in adults, such as Alzheimer's and Parkinson's diseases.

Pathway 1: Biomarker Development

BPAN is caused by changes (called pathogenic variants) in the gene WDR45 on the X chromosome, and the disease affects each child differently. Some experience severe symptoms, while others have milder forms of this condition. To understand these differences and better predict which children will have a more severe disease course, we are studying neurons grown from the blood cells of children with BPAN, and in some cases we will engineer similar cells to model patient-specific changes in the WDR45 gene that circumvent issues related to X inactivation.

By comparing neurons and gene changes from children with severe symptoms to those from children with milder symptoms, we aim to find specific biomarkers—biological clues—that indicate how severe the disease might become. These biomarkers could include differences in how cells manage waste (a process called autophagy); how they respond to stress (a process called ferroptosis); and how their basic functions, such as information processing, are affected by the disease. By identifying these biomarkers, we will be better equipped to predict how BPAN will progress in a newly diagnosed child, and we will also have more information about how a specific individual's genetic change influences the biology of the brain, which can help to tailor therapies.

In separate work, we are deriving biomarkers of BPAN neurodegeneration in mice engineered to express changes in WDR45, similar to children with BPAN. We are using approaches that can be employed in the clinic, such as MRI, EEG, movement analysis, metabolomics, and proteomics. This approach will help us understand how to quantify BPAN severity and response to new therapies in the future.

Pathway 2: High Throughput Drug Screening

Currently, there are no treatments that can stop or slow the progression of BPAN. However, there may be existing drugs and compounds (perhaps even some that are already approved for use in children) that will have a therapeutic impact. We will screen large libraries containing thousands of drugs in cells engineered to express BPAN genetic changes at the Stanford High-Throughput Screening Center @ The Nucleus at Sarafan ChEM-H, a vital resource for the Stanford research community. This center provides the expertise and technology needed for large-scale screenings to rapidly advance drug discoveries.

Specifically, we will use a multi-tier approach to determine whether drugs can restore proper autophagy and other key metrics of neuronal health in cell lines expressing BPAN WDR45 variants (genetic changes), as well as in neurons derived directly from children with BPAN. Drugs that meet these criteria would then become key candidates for future clinical trials. Once we identify the most promising drug candidates, we will test them in mouse models of BPAN, measuring the most precise biomarkers identified in Pathway 1.